<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069339</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-07</org_study_id>
    <nct_id>NCT03069339</nct_id>
  </id_info>
  <brief_title>Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B &amp; C Cirrhosis</brief_title>
  <official_title>Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B &amp; C Cirrhosis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: Open labeled randomized controlled trial. The study will be conducted on&#xD;
      patients attending outpatient or admitted to admitted to Department of Hepatology from&#xD;
      January 2017 to December 2018 at ILBS, New Delhi&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the incidence of first variceal bleed at 1 year.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and bleed related Survival in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleed related Survival in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Child-Turcotte-Pugh (CTP) score in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Model for End Stage Liver Disease (MELD) score in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Spontaneous Bacterial Peritonitis (SBP) in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Kidney Injury (AKI) in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Shock in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new ascites in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HVPG response at 1year in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related side effects in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EVL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Variceal Ligation</intervention_name>
    <description>EVL will be done every 3 weeks till eradication</description>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
    <arm_group_label>EVL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver Cirrhotics between 18-70 yrs of age (cirrhosis diagnosed on the basis of&#xD;
             clinical, biochemical, fibroscan &amp; imaging.)&#xD;
&#xD;
          -  CTP ≥ 7-15 (Child's B/C)&#xD;
&#xD;
          -  Small esophageal varices with RCS and large esophageal varices (&gt;5 mm)&#xD;
&#xD;
          -  No history of previous bleed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy-HCC, PVT&#xD;
&#xD;
          -  Child A&#xD;
&#xD;
          -  MELD &gt;35&#xD;
&#xD;
          -  Contraindications to β blockers.&#xD;
&#xD;
          -  Platelet count &lt; 30,000/mm3&#xD;
&#xD;
          -  Previous endoscopic variceal treatment. (Beyond 21 days)&#xD;
&#xD;
          -  Patients having an indication for TIPS or requiring more than 1 therapeutic ascitic&#xD;
             tapping/month&#xD;
&#xD;
          -  Post TIPS, Shunt surgery&#xD;
&#xD;
          -  Acute kidney injury (Sr.Cr&gt;1.5mg/dl)&#xD;
&#xD;
          -  Non cirrhotic portal hypertension&#xD;
&#xD;
          -  Acute on chronic liver failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

